Search research articles
Contact Us
Filters
Showing results (171-180 of 232) with videos related to
Page
of 24
Sort By:
Blood
|
January 7, 2022
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML
Gabrielle Paras, Linde M Morsink, Megan Othus, et al.
Leukemia
|
March 17, 2026
Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?
Lucia Turcsanyi, Xiao-Shuai Zhang, Milos Kudelka, et al.
Journal for Immunotherapy of Cancer
|
September 29, 2024
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors
Young Kwang Chae, Megan Othus, Sandip Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 22, 2014
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
Lawrence E Flaherty, Megan Othus, Michael B Atkins, et al.
Cancers
|
August 23, 2020
Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
Linde M Morsink, Brenda M Sandmaier, Megan Othus, et al.
Haematologica
|
April 6, 2023
Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network
Christina M Termini, Anna Moseley, Megan Othus, et al.
Therapeutic Advances in Medical Oncology
|
November 25, 2024
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
British Journal of Haematology
|
February 18, 2014
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy
Steven E Coutre, Megan Othus, Bayard Powell, et al.
JCO Precision Oncology
|
October 31, 2019
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
Aziz Nazha, Mikkael A Sekeres, Rafael Bejar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2024
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers
Young Kwang Chae, Lucy Corthell, Sandip Pravin Patel, et al.
Page
of 24
Search research articles
Search
Showing results (171-180 of 232) with videos related to
Sort By:
Page
of 24
Blood
|
January 7, 2022
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML
Gabrielle Paras, Linde M Morsink, Megan Othus, et al.
Leukemia
|
March 17, 2026
Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?
Lucia Turcsanyi, Xiao-Shuai Zhang, Milos Kudelka, et al.
Journal for Immunotherapy of Cancer
|
September 29, 2024
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors
Young Kwang Chae, Megan Othus, Sandip Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 22, 2014
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
Lawrence E Flaherty, Megan Othus, Michael B Atkins, et al.
Cancers
|
August 23, 2020
Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
Linde M Morsink, Brenda M Sandmaier, Megan Othus, et al.
Haematologica
|
April 6, 2023
Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network
Christina M Termini, Anna Moseley, Megan Othus, et al.
Therapeutic Advances in Medical Oncology
|
November 25, 2024
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
British Journal of Haematology
|
February 18, 2014
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy
Steven E Coutre, Megan Othus, Bayard Powell, et al.
JCO Precision Oncology
|
October 31, 2019
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
Aziz Nazha, Mikkael A Sekeres, Rafael Bejar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2024
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers
Young Kwang Chae, Lucy Corthell, Sandip Pravin Patel, et al.
Page
of 24